Marcy l’Étoile, France – bioMérieux, a world leader in the field of in vitro diagnostics, today announces that its BIOFIRE® Joint Infection (JI) Panel has received De Novo authorization from the US Food and Drug Administration (FDA). This panel tests for 31 pathogens implicated in most acute joint infections, and also includes 8 antimicrobial resistance (AMR) […]

PolarityTE announced that the Company will effectuate a 1-for-25 reverse stock split of the Company’s issued and outstanding common stock.

PolarityTE provided a business update and reported financial results for the three-month period ended March 31, 2022.